Vivus costs skyrocket on Qsymia launch; Lilly bone drug fails in head-to-head back-pain trial;

@FiercePharma: Generics trounced Big Pharma's Q2 results. Who benefited? Our 11 Fastest-Growing Generics Companies. Special Report | Follow @FiercePharma

>Vivus ($VVUS) costs leapt by almost half in the second quarter, as the drugmaker prepared to launch its new obesity drug Qsymia, but Lazard Capital Markets raised the company to "buy," saying patent worries could be resolved with a royalty to Johnson & Johnson ($JNJ). Report | Report

> Eli Lilly's ($LLY) bone drug Forteo failed to best generic Actonel at alleviating back pain in postmenopausal women with vertebral fractures from osteoporosis. Report

> German generics maker Stada reported a 14% drop in net income, worse than analysts expected, thanks to slow domestic sales and costs related to restructuring, but the company expects to meet its profits forecast for the year. Report

> A Pacific region trade deal could hamper access to AIDS drugs, activists say, by privileging patent protection. Report

> Generics maker Akorn ($AKRX) hiked its full-year forecast after strong sales of its Vancocin generic boosted second quarter results. Report

> Ugandan regulators banned 67 medicines from India's Flamingo, including anti-fungals, anti-malarials, steroids and painkillers, saying the products were substandard. Report

Medical Device News

@FierceMedDev: One way to address device hacking? A wrist-watch-like device that measures biometrics as a kind of security I.D. More | Follow @FierceMedDev

 @MarkHFierce: CardioDx gained a crucial win: Medicare coverage for a coronary artery disease test. More | Follow @MarkHFierce

 @DamianFierce: In keeping with its plans to slim down, Boston Scientific is cutting 50 jobs in Ireland. More | Follow @DamianFierce

> Roche Diagnostics ramps up for double-digit growth in India. Item

> Wright subpoenaed over metal hip implants. News

Biotech News

 @FierceBiotech: Fuji Pharma jumps into CMO game with $53.4M plant buy. More | Follow @FierceBiotech

 @JohnCFierce: Lundbeck's Phase II Alzheimer's drug that boosts cognition chemicals looks interesting. Harder to do deals now post-bapi? More | Follow @JohnCFierce

 @RyanMFierce: Lots of a Big Pharma news this week, mostly bad. How about some startup action? Good or bad. | Follow @RyanMFierce

> Novartis keeps U.K. respiratory unit after layoffs. Item

> Billionaire's biotech seals second deal with Synthetic Biologics. News

> AstraZeneca pulls the plug on sepsis drug after trial tanks. News

> Infinity Pharma axes 20% of jobs. Story

Biomarkers News

> Faster BRCA mutation identification could help families at risk. Story

> Prostate gene deficit could boost tumor growth. Item

> Brain signals when 'Special K' will do the trick. More

> Researchers find East Asian TKI resistance gene. Article

Drug Delivery News

> U.S. submission for Durect's Posidur is in the works. More

> Pluristem PLX cells turn around near fatal bone marrow failure. Article

> Endocyte's kidney conjugates get right to the spot. Story

> Swimming microbots could deliver drugs. Item

> Talon pins its hopes on Marqibo FDA approval. Report

And Finally ... Millions of American could be taking a "wonder drug" but don't, public health officals said. It's exercise. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.